Palvella Therapeutics Inc.

01/08/2025 | Press release | Distributed by Public on 01/08/2025 07:21

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.